To the full analysis
Laboratorios Farmaceuticos Rovi stock: growth
ROVI.MCLaboratorios Farmaceuticos Rovi reported $823.85M in revenue for fiscal 2025, down 2.7% on the prior year, up 12.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
12.6%
per year from 2006 to 2025, per share 12.4%
Earnings (Annual rate)
19.1%
per year from 2006 to 2025, per share 19.7%
Free cash flow (Annual rate)
20.1%
per year from 2006 to 2025, per share 20%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 12.1% | 11.7% | 12.6% |
| Revenue per share | 13.9% | 11.3% | 12.4% |
| Earnings | 18.1% | 21.6% | 19.1% |
| Earnings per share | 20.1% | 21.3% | 19.7% |
| Free cash flow | 75.7% | 28.9% | 20.1% |
| Free cash flow per share | 78.5% | 28.5% | 20.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $87.13M | $5.61M | $4.07M |
| 2007 | $111.6M | $16.57M | −$11.73M |
| 2008 | $141.33M | $26.09M | $3.24M |
| 2009 | $127.61M | $25.64M | $7.35M |
| 2010 | $175.79M | $27.24M | $17.3M |
| 2011 | $204.67M | $20.09M | $4.8M |
| 2012 | $223.75M | $21.62M | $6.53M |
| 2013 | $241.11M | $25.51M | $5.69M |
| 2014 | $263.78M | $26.72M | −$2.27M |
| 2015 | $272.6M | $21.95M | $10.52M |
| 2016 | $293.83M | $28.91M | $30.42M |
| 2017 | $305.45M | $19.1M | −$2.11M |
| 2018 | $335.98M | $19.83M | −$19.87M |
| 2019 | $422.53M | $43.52M | −$54.93M |
| 2020 | $465.36M | $67.66M | $7.96M |
| 2021 | $718.8M | $169.62M | $120.23M |
| 2022 | $906.09M | $221.25M | $206.34M |
| 2023 | $919.18M | $188.75M | $64.34M |
| 2024 | $846.31M | $151.68M | $84.28M |
| 2025 | $823.85M | $155.62M | $133.15M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Apr 2025)
- Valuation signal Undervalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.